Get the Stockscreener App
5.04
1.18%
-0.06
After Hours:
5.05
0.010
+0.20%
Puma Biotechnology Inc stock is traded at $5.04, with a volume of 490.98K.
It is down -1.18% in the last 24 hours and down -1.75% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$5.10
Open:
$5.13
24h Volume:
490.98K
Relative Volume:
0.78
Market Cap:
$253.87M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
8.2623
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
-4.36%
1M Performance:
-1.75%
6M Performance:
+57.01%
1Y Performance:
+70.85%
1-Day Range:
$5.00
$5.22
1-Week Range:
$5.00
$5.515
52-Week Range:
$2.32
$6.07
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
5.04 | 256.89M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
How strong is Puma Biotechnology Inc. stock revenue growthMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Using R and stats models for Puma Biotechnology Inc. forecasting2025 Institutional Moves & Weekly High Potential Alerts - newser.com
Using Ichimoku Cloud for Puma Biotechnology Inc. technicalsPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
How institutional buying supports Puma Biotechnology Inc. stockMarket Activity Report & Daily Oversold Bounce Ideas - newser.com
Is Puma Biotechnology Inc. reversing from oversold territoryJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Can Puma Biotechnology Inc. stock withstand economic slowdown2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
Global Desmoid Tumors Market Report 2025: Regional and Country-Level Analysis & Forecast to 2035 Featuring SpringWorks Therapeutics, Ayala Pharma, Puma Biotechnology, BMS, Eli Lilly, Ipsen, Deciphera Pharma - Yahoo Finance
Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Will Puma Biotechnology Inc. stock remain a Wall Street favorite - fcp.pa.gov.br
Why retail investors favor Puma Biotechnology Inc. stockInflation Watch & Safe Entry Momentum Tips - fcp.pa.gov.br
Puma Biotechnology Stock Up 11%, Buy Or Wait? - Trefis
Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold (C+) Rating by Weiss Ratings - MarketBeat
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2025 Financial Results - BioSpace
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - The AI Journal
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN
Why Puma Biotechnology Inc. is moving todayJuly 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
Is Puma Biotechnology Inc. stock a safe investment in uncertain marketsProduct Launch & Short-Term Trading Opportunity Alerts - newser.com
Chart overlay techniques for tracking Puma Biotechnology Inc.Fed Meeting & Smart Money Movement Alerts - newser.com
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):